
    
The genomic variant c.2722G>C p.Gly908Arg rs796052984 on the SCN1A gene is a missense mutation that results in the substitution of glycine with arginine at the 908th amino acid position. This variant was identified in a patient (P21) who presented with developmental delay (DD) and was characterized by early infantile epileptic encephalopathy (EIEE), which is a severe form of epilepsy that begins in infancy [1]. The SCN1A gene encodes the alpha-1 subunit of the type 1 voltage-gated sodium channel (Nav1.1), which is critical for the initiation and propagation of action potentials in neurons. Mutations in SCN1A can lead to a variety of epilepsy syndromes, including Dravet syndrome (DS), generalized epilepsy with febrile seizures plus (GEFS+), and other forms of epilepsy characterized by febrile seizures.The c.2722G>C variant has been submitted to ClinVar with mixed interpretations of pathogenicity, including one submission classified as pathogenic and three with uncertain significance. This discrepancy in classification underscores the complexity of variant interpretation and the need for further functional studies or additional evidence to clarify the clinical relevance of this specific mutation.Given the established role of SCN1A in neuronal excitability and the association of other mutations in this gene with epilepsy syndromes, the c.2722G>C p.Gly908Arg variant is likely to have functional consequences that contribute to the patient's neurological phenotype. However, the exact mechanism by which this amino acid change affects the function of the Nav1.1 channel remains to be elucidated. Further research is necessary to determine the impact of this variant on channel function and its contribution to the clinical manifestations observed in the patient.

SCN1A遺伝子におけるゲノム変異c.2722G>C p.Gly908Arg rs796052984は、ミスセンス変異であり、908番目のアミノ酸位置でグリシンがアルギニンに置換される結果をもたらします。この変異は、発達遅延（DD）を呈し、乳児期早期に発症する重度のてんかんである早発型乳児てんかん性脳症（EIEE）と特徴づけられる患者（P21）で確認されました[1]。SCN1A遺伝子は、タイプ1電位依存性ナトリウムチャネル（Nav1.1）のα1サブユニットをコードしており、ニューロンにおける活動電位の開始と伝播に重要な役割を果たします。SCN1Aの変異は、Dravet症候群（DS）、熱性けいれんを伴う全般性てんかん（GEFS+）、および熱性けいれんを特徴とするその他のてんかん症候群を含むさまざまなてんかん症候群を引き起こす可能性があります。

c.2722G>C変異はClinVarに提出されており、その病原性に関する解釈は混在しており、1件は病原性と分類され、3件は不明な意義とされています。この分類の不一致は、変異解釈の複雑さを浮き彫りにしており、この特定の変異の臨床的関連性を明確にするために、さらなる機能研究や追加の証拠が必要であることを示しています。

SCN1Aがニューロンの興奮性において果たす確立された役割と、この遺伝子の他の変異がてんかん症候群と関連していることを考慮すると、c.2722G>C p.Gly908Arg変異は患者の神経学的表現型に寄与する機能的な影響を持つ可能性が高いです。しかし、このアミノ酸変化がNav1.1チャネルの機能にどのように影響を与えるかの正確なメカニズムはまだ解明されていません。この変異がチャネル機能に与える影響と患者に観察される臨床的症状への寄与を明らかにするためには、さらなる研究が必要です。
    
## References
- [1] Viswanathan LG et al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Waheed S et al. (2024). "Identification and In-Silico study of non-synonymous functional SNPs in the human SCN9A gene." PloS one, 19(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38394191/)
- [3] Iorio F et al. (2016). "A Landscape of Pharmacogenomic Interactions in Cancer." Cell, 166(3) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/27397505/)
- [4] Encinas AC et al. (2020). "Variable patterns of mutation density among NaV1.1, NaV1.2 and NaV1.6 point to channel-specific functional differences associated with childhood epilepsy." PloS one, 15(8) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/32845893/)
- [5] Yang F et al. (2015). "Protein domain-level landscape of cancer-type-specific somatic mutations." PLoS computational biology, 11(3) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25794154/)
- [6] Adalsteinsson VA et al. (2017). "Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors." Nature communications, 8(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/29109393/)
- [7] Giannakis M et al. (2016). "Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma." Cell reports, 15(4) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/27149842/)
- [8] Xie M et al. (2014). "Age-related mutations associated with clonal hematopoietic expansion and malignancies." Nature medicine, 20(12) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25326804/)
- [9] Lu C et al. (2015). "Patterns and functional implications of rare germline variants across 12 cancer types." Nature communications, 6() [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/26689913/)
- [10] Wang X et al. (2023). "Newborn genetic screening is highly effective for high-risk infants: A single-centre study in China." Journal of global health, 13() [PubMed](https://pubmed.ncbi.nlm.nih.gov/37824171/)

    
## ClinVar Submissions
- **[RCV000188895](https://www.ncbi.nlm.nih.gov/clinvar/RCV000188895/)**: not provided
- **[RCV002265107](https://www.ncbi.nlm.nih.gov/clinvar/RCV002265107/)**: not provided
- **[RCV002427740](https://www.ncbi.nlm.nih.gov/clinvar/RCV002427740/)**: Inborn genetic diseases
- **[RCV003095983](https://www.ncbi.nlm.nih.gov/clinvar/RCV003095983/)**: Early infantile epileptic encephalopathy with suppression bursts

    